Core Viewpoint - The company has received acceptance from the National Medical Products Administration (NMPA) for the New Drug Application (NDA) of its investigational drug, TY-9591, which is a deuterated derivative of Osimertinib, targeting advanced or metastatic non-small cell lung cancer (NSCLC) patients with specific EGFR mutations [1][2] Group 1: Drug Development and Clinical Trials - TY-9591 is designed for first-line treatment of adult patients with locally advanced or metastatic NSCLC who have EGFR exon 19 deletions (19DEL) or exon 21 (L858R) mutations, along with CNS metastases [1] - Phase I (TYKM1601101) and Phase II (TYKM1601201) clinical trial data have shown excellent intracranial and overall response rates in NSCLC patients with brain metastases, indicating significant clinical benefits and addressing unmet medical needs [1] - Key Phase II clinical trial data (TYKM1601202) further confirms the superior efficacy of TY-9591 over Osimertinib in terms of intracranial response rates and clinical benefits [1] Group 2: Clinical Value and Advantages - As a deuterated compound of Osimertinib, TY-9591 demonstrates enhanced clinical value and advantages across various aspects, including chemical structure, pharmacological action, clinical efficacy, safety, and resistance mechanism analysis [2] - The drug shows a significant improvement in disease prognosis for patients, highlighting its potential impact on treatment outcomes [2]